Chronic hepatitis C
Drug research and approvals for chronic hepatitis C: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 12 studies of chronic hepatitis C are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 11 approved and 0 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 12
- Trials authorized in Canada: 0
- FDA orphan approvals: 11
- EU medicines: 6
- Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to…NCT07487623 · Not applicable · University of Guadalajara · starts Oct 11, 2025
- Scaling Up Point-of-Care Hepatitis C Testing and Treatment in CanadaNCT07095192 · Not reported · McGill University · starts May 20, 2025
- Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of…NCT06658782 · Not reported · University of Oxford · starts May 1, 2025
- The Efficacy of Vosevi in Treating DAA-experienced PatientsNCT06180590 · Not reported · The Third Affiliated Hospital of Guangzhou Medical University · starts Feb 28, 2023
- Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese…NCT05870969 · Not reported · Ruijin Hospital · starts Mar 1, 2023
- Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With CancerNCT05181826 · Not reported · Helio Genomics · starts May 21, 2019
- "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and…NCT04690972 · Not reported · Institut National de la Santé Et de la Recherche Médicale, France · starts Jan 14, 2021
- Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirNCT03855917 · Phase 4 · Kirby Institute · starts Feb 11, 2020
- Effect of Some Drugs on Liver FibrosisNCT03770936 · Phase 3 · Sherief Abd-Elsalam · starts Oct 1, 2018
Approved 22
- RibavirinInosine-5'-monophosphate dehydrogenase 1 inhibitor
- Peginterferon alfa-2aInterferon alpha/beta receptor agonist
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- SofosbuvirRNA-directed RNA polymerase inhibitor
- ParitaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- OmbitasvirNonstructural protein 5A inhibitor
- TelaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- DasabuvirRNA-directed RNA polymerase inhibitor
- DaclatasvirNonstructural protein 5A inhibitor
- SimeprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- BoceprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- LedipasvirNonstructural protein 5A inhibitor
- GrazoprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- PibrentasvirNonstructural protein 5A inhibitor
- GlecaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- ElbasvirNonstructural protein 5A inhibitor
- VelpatasvirNonstructural protein 5A inhibitor
- Interferon alfa-2bInterferon alpha/beta receptor agonist
- VoxilaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- EltrombopagThrombopoietin receptor agonist
- Interferon alfaCON-1Interferon alpha/beta receptor agonist
Phase 3 12 of 22
- FaldaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- DanoprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- DeleobuvirRNA-directed RNA polymerase inhibitor
- VaniprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- Albinterferon alfa-2bInterferon alpha/beta receptor agonist
- Polyethylene glycol 3350Osmotic laxative
- Interferon alfa
- AmantadineGlutamate [NMDA] receptor antagonist
- Peginterferon lambda-1aInterferon lambda receptor agonist
- AsunaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- CyclosporineCyclophilin A modulator
- Thymalfasin
Phase 2 12 of 50
- MericitabineRNA-directed RNA polymerase inhibitor
- VedroprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- NitazoxanidePyruvate:ferredoxin oxidoreductase inhibitor
- OdalasvirNonstructural protein 5A inhibitor
- AdafosbuvirRNA-directed RNA polymerase inhibitor
- TegobuvirRNA-directed RNA polymerase inhibitor
- NarlaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- CelgosivirAlpha glucosidase inhibitor
- RadalbuvirRNA-directed RNA polymerase inhibitor
- Interferon gamma-1bInterferon gamma receptor agonist
- SetrobuvirRNA-directed RNA polymerase inhibitor
- LomibuvirRNA-directed RNA polymerase negative allosteric modulator
Phase 1 or earlier 12 of 25
- ItraconazoleCytochrome P450 51 inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- TamoxifenEstrogen receptor alpha modulator
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- Ethinyl estradiolEstrogen receptor alpha agonist
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- LevonorgestrelProgesterone receptor agonist
- OmeprazolePotassium-transporting ATPase inhibitor
- CaffeineAdenosine receptor antagonist
- TolbutamideSulfonylurea receptor 1, Kir6.2 blocker
- NamodenosonAdenosine A3 receptor agonist
- BaminerceptHeterotrimeric lymphotoxin LTa1b2 inhibitor
How its trials ended
1,092 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 418 whose ending is known, 62% met their primary endpoint, 5% missed it and 32% stopped early.
- Completed, result not reported52748%
- Met its primary endpoint26124%
- Status unknown13012%
- Stopped: other or unclear838%
- Stopped: enrollment or feasibility313%
- Missed its primary endpoint222%
- Ongoing172%
- Stopped: sponsor or business decision101%
- Stopped: lack of efficacy5<1%
- Stopped: safety3<1%
- Stopped: funding3<1%
| Jun 10, 2021 | EpclusaTreatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6… | Gilead Sciences, Inc. | Approved |
| Jun 10, 2021 | MavyretTreatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection… | AbbVie, Inc. | Approved |
| Mar 19, 2020 | EpclusaEPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)… | Gilead Sciences, Inc. | Approved |
| Apr 30, 2019 | MavyretMAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis… | AbbVie, Inc. | Approved |
| Apr 7, 2017 | SovaldiTreatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without… | Gilead Sciences, Inc. | Approved |
| Apr 7, 2017 | HarvoniTreatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6… | Gilead Sciences, Inc. | Approved |
| Jul 29, 2003 | RebetolTreatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older. | Schering Corporation | Approved |
| Jul 26, 2017 | MaviretGlecaprevir; pibrentasvir | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Jul 26, 2017 | VoseviSofosbuvir; velpatasvir; voxilaprevi | Gilead Sciences Ireland UC | EMA ↗ |
| Jul 22, 2016 | ZepatierElbasvir; grazoprevir | Merck Sharp & Dohme B.V. | EMA ↗ |
| Jul 6, 2016 | EpclusaSofosbuvir; velpatasvir | Gilead Sciences Ireland UC | EMA ↗ |
| Nov 17, 2014 | HarvoniLedispavir; sofosbuvir | Gilead Sciences Ireland UC | EMA ↗ |
| Jan 16, 2014 | SovaldiSofosbuvir | Gilead Sciences Ireland UC | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA